Race Oncology Limited (“Race”) is pleased to provide shareholders with a strategic update, including an overview of revisions to corporate strategy, designed to optimise use of existing resources, while driving bisantrene’s commercial partnering and collaboration potential. Key highlights: Read the…
Race Oncology Limited (ASX:RAC) is an Australian pharmaceutical company focused on the development of its key drug, Zantrene, which is currently being studied for pre-clinical and clinical efficacy in several cancer indications. Zantrene is a highly targeted precision oncology agent…
To discuss or comment on this announcement please visit our Investor Hub.
8 November 2021 – Race Oncology Limited (“Race”) is pleased to announce that it has entered into a strategic collaborative research agreement with the University of Wollongong (UOW) to undertake preclinical evaluation of new Zantrene formulations designed by Race. This…
A Perth family tells the story of their son’s battle with Acute Myeloid Leukaemia. When Kai got sick, they searched the world for answers.
Race Oncology is pleased to announce the company has been invited to present at the ‘Biotech Showcase’ during the J.P. Morgan Healthcare Conference in San Francisco next week. Race Oncology Chief Executive Peter Molloy will present on Monday 8 January,…
